Multiconsult ASA (0R8N)
London Exchange · UK · prices in NOK · close of 19 Oct 2026
Key indicators
| Last close | NOK 131.10 |
|---|---|
| 52-week range | 128.90 – 181.50 |
| Return, 1 month / 3 months | −10.6% / – |
| Return, 1 year / 3 years | −21.0% / +14.6% |
| Trend | Below its 200-day average |
| RSI (14) | 35 |
| Volatility (1 year) | 26.1% |
| Worst drawdown (1 year) | -26.6% |
| Average daily value traded | 0.03M NOK |
| Dividend yield | 3.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Multiconsult is a Norwegian engineering consultancy based in Oslo. It provides design, engineering and project management services for buildings, transport infrastructure, energy and water projects. Its clients include public authorities, municipalities and private developers, and its work spans planning, technical advisory and construction-phase support. The firm operates through a network of offices in Norway and abroad, serving both domestic and international markets.
Multiconsult ASA trades under the code 0R8N on the London Exchange in UK, with its price quoted in Norwegian kroner (NOK). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Multiconsult ASA (0R8N) trades on the London Exchange in UK. It last closed at NOK 131.10 on 19 October 2026.
Its price-based Market X-Ray is 39 out of 100 (a weak price profile), ranking 2,708 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 21.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 34 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | – | ||
| From 52-week high | -27.8% | ||
| Momentum | 24 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | – | ||
| 6-month return | -20.6% | ||
| 12-month return, skipping the last month | -11.6% | ||
| Stability (higher is calmer) | 65 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 26.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.6% | ||
| Liquidity | 19 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.03M NOK | ||
| Zero-volume days | 0.0% | ||
| Income | 52 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 3.8% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −0.5% |
|---|---|
| 1 month | −10.6% |
| 3 months | – |
| 6 months | −20.6% |
| 1 year | −21.0% |
| 3 years | +14.6% |
| 5 years | −9.8% |
Signals
| 50-day / 200-day average | 146.55 / 162.78 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.97 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 17 Apr 2026 | NOK 5.0000 |
| 11 Apr 2025 | NOK 10.0000 |
| 12 Apr 2024 | NOK 8.0000 |
| 14 Apr 2023 | NOK 9.0000 |
| 8 Apr 2022 | NOK 6.0000 |
| 20 Apr 2021 | NOK 8.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.